Trovagene

Trovagene releases phase I study results supporting development of PCM-075 in AML

Monday, May 29, 2017

Trovagene, a precision medicine biotechnology company, announced summary data from a phase I safety study conducted by Nerviano Medical Sciences with PCM-075, a polo-like kinase 1 (PLK1) inhibitor. This data is supportive of a planned phase I/II clinical trial in patients with acute myeloid leukemia (AML) and is now being submitted for peer review publication by study investigators.

[Read More]

Trovagene, Genomac expand collaboration

Wednesday, January 21, 2015

Trovagene, a provider of technology for the detection and monitoring of cell-free DNA headquartered in San Diego, will expand its clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer.

[Read More]

Peter Hirth joins Trovagene’s scientific advisory board

Friday, August 15, 2014

Trovagene, a California-based developer of cell-free molecular diagnostics, has hired K. Peter Hirth, Ph.D., who joins the company’s scientific advisory board. A pioneer in the field of personalized medicine, Hirth led the organizations that developed both Sutent and Zelboraf; two successful targeted cancer therapeutics.

[Read More]